Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3200 Diagnostic effectiveness of Chromogranin A and multigene liquid biopsy (NETest) in neuroendocrine neoplasia: A prospective comparative evaluation of monoanalyte and multianalyte biomarker efficacy

Introduction: The absence of a reliable, universal biomarker is a significant limitation in neuroendocrine neoplasia (NEN) management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Malczewska A

Authors: Malczewska A, Oberg K, Kos-Kudla B,

Keywords: CgA, NETest, diagnostic, biomarker, NEN, genomic analysis, elisa,

#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood

Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Oberg K

Authors: Öberg K, Califano A, Strosberg J, Ma S, Pape U,

Keywords: NETest, Meta-analysis, biomarker, in vitro diagnostic, diagnostic, management, NET, AUC, ROC,

#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,

Keywords: serotonin, diarrhea ,

#1208 Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Öberg K, Leyden J, Sissons M, Kolarova T, Goldstein G,

Keywords: Multidisciplinary team,